JP2022525439A - プロゲステロンを含むevaセグメント化膣内リング - Google Patents
プロゲステロンを含むevaセグメント化膣内リング Download PDFInfo
- Publication number
- JP2022525439A JP2022525439A JP2021560625A JP2021560625A JP2022525439A JP 2022525439 A JP2022525439 A JP 2022525439A JP 2021560625 A JP2021560625 A JP 2021560625A JP 2021560625 A JP2021560625 A JP 2021560625A JP 2022525439 A JP2022525439 A JP 2022525439A
- Authority
- JP
- Japan
- Prior art keywords
- eva
- ring
- day
- ivr
- progesterone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims abstract description 119
- 239000000186 progesterone Substances 0.000 title claims abstract description 52
- 229960003387 progesterone Drugs 0.000 title claims abstract description 52
- 208000005107 Premature Birth Diseases 0.000 claims abstract description 41
- 230000029849 luteinization Effects 0.000 claims abstract description 9
- 230000004064 dysfunction Effects 0.000 claims abstract description 7
- 230000000938 luteal effect Effects 0.000 claims abstract description 5
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims description 81
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 22
- 239000006213 vaginal ring Substances 0.000 claims description 20
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- 229940044953 vaginal ring Drugs 0.000 claims description 15
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 14
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 14
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 14
- 230000000638 stimulation Effects 0.000 claims description 14
- 239000000835 fiber Substances 0.000 claims description 13
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 11
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 11
- 229940040129 luteinizing hormone Drugs 0.000 claims description 11
- 238000003780 insertion Methods 0.000 claims description 10
- 230000037431 insertion Effects 0.000 claims description 10
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 6
- 230000001850 reproductive effect Effects 0.000 claims description 6
- 206010036590 Premature baby Diseases 0.000 claims description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 230000010349 pulsation Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000012868 Overgrowth Diseases 0.000 claims description 3
- 102000003946 Prolactin Human genes 0.000 claims description 3
- 108010057464 Prolactin Proteins 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 230000002267 hypothalamic effect Effects 0.000 claims description 3
- 230000009245 menopause Effects 0.000 claims description 3
- 230000003821 menstrual periods Effects 0.000 claims description 3
- 230000005906 menstruation Effects 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 229940097325 prolactin Drugs 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 201000000736 Amenorrhea Diseases 0.000 claims description 2
- 206010001928 Amenorrhoea Diseases 0.000 claims description 2
- 231100000540 amenorrhea Toxicity 0.000 claims description 2
- 238000009164 estrogen replacement therapy Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000004904 shortening Methods 0.000 abstract description 4
- 238000010586 diagram Methods 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 45
- 238000000034 method Methods 0.000 description 16
- 229940068196 placebo Drugs 0.000 description 15
- 239000000902 placebo Substances 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 14
- 238000011282 treatment Methods 0.000 description 13
- 206010015150 Erythema Diseases 0.000 description 11
- 210000003679 cervix uteri Anatomy 0.000 description 11
- 231100000321 erythema Toxicity 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- 229940087667 prometrium Drugs 0.000 description 9
- 210000001215 vagina Anatomy 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 241001494479 Pecora Species 0.000 description 6
- 229940000593 crinone Drugs 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 4
- 239000003433 contraceptive agent Substances 0.000 description 4
- 230000002254 contraceptive effect Effects 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 230000004720 fertilization Effects 0.000 description 4
- 238000009474 hot melt extrusion Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000009897 systematic effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000009806 oophorectomy Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 208000002254 stillbirth Diseases 0.000 description 3
- 231100000537 stillbirth Toxicity 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 210000003905 vulva Anatomy 0.000 description 3
- 238000003466 welding Methods 0.000 description 3
- MXDOOIVQXATHKU-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXDOOIVQXATHKU-RYVPXURESA-N 0.000 description 2
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 102100026816 DNA-dependent metalloprotease SPRTN Human genes 0.000 description 2
- 101710175461 DNA-dependent metalloprotease SPRTN Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 239000012943 hotmelt Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 229940044950 vaginal gel Drugs 0.000 description 2
- 239000000029 vaginal gel Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920013683 Celanese Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022840 Intraventricular haemorrhage Diseases 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 description 1
- 229960005473 fenbendazole Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 201000010759 hypertrophy of breast Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940015467 makena Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 229940115044 nuvaring Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003146 progesterones Chemical class 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/43—Hormones, e.g. dexamethasone
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Surgical Instruments (AREA)
- Steroid Compounds (AREA)
Abstract
Description
本出願は、2019年3月29日に出願された米国特許第62/826,978号および2019年5月3日に出願された米国特許第62/843,288号に対する優先権の利益を主張する。それらの開示は、図面を含めて、参照により本明細書に組み込まれる。
本明細書に開示されるEVAリングは、まだ閉経に達していないが、体内のプロゲステロンの不足のために月経(period)を有しない女性において月経期(menstrual period)を引き起こすために使用することができる。
Pを放出することができる膣内リングを、以前に記載されたものと同様の様式で調製した。全体のプロセスを図1に示す。すべてのリング製造を、QPharma(Malmo,Sweden)で行った。このプロセスは、ペレットの配合、ファイバーの押出、それに続く熱溶接によるファイバーの接合を含んでいた。ブレンディングを、Turbulaミキサー(モデルT 10 B、17リットルのステンレス鋼混合容器、Glenn Mills、Clifton,NJ)を使用して行った。得られたブレンドを、二軸押出機(Pharma 11重量分析フィーダーを備えたPharma 11二軸ホットメルト押出機)を使用するホットメルト押出によって配合し、Pharma 11空冷コンベヤーに供給し、続いてPharma 11 Vericut Pelletizor(Thermo Fisher Scientific、Dreieich,Germany)を使用してペレット化した。ペレットを、25mm単軸押出機(Dr Collin、Ebersberg,Germany)を使用してホットメルト押出よってファイバーに形成した。得られたファイバーを、Dr Collinインラインカッティングステーションを使用して切断した。切断したファイバー(またはセグメント)を、Automationspartnerシングルステーションラボ溶接機(Ramlosa、Sweden)を使用して溶接した。
ヒツジの試験を行う前に、3つのIVR製剤からのPの放出速度をインビトロで測定して、目標の放出速度が達成されたかどうかを決定した。放出速度は、37℃のシェーカーで、放出媒体として200mLの0.5%ドデシル硫酸ナトリウムを使用してテストした。サンプリング(2mL)を、6時間目、1~4日目、7~11日目、14、15、18、21、22、25、および28日目に行った。Pの濃度を、UV検出を使用する検証済みの逆相液体クロマトグラフィー法を使用して決定した。使用したカラムは、Phenomenex Luna C8(2)、150mm×3.0mm、5μmであった。使用したガードカラムは、Phenomenex C8(4mm×3mm)であった。移動相は、精製水中のアセトニトリル45%(55%)、v/vであった。注入量は、10μLであった。Pを245nmのUVで検出した。Pの標準曲線の範囲は、0.00625~0.25mg/mLであった。これらの濃度にわたって、曲線は、線形であった(相関係数>0.997)。6つのIVRを各溶解時点でテストした。
本試験の目的は、薬物未投与の卵巣摘出した雌のDorset交雑種ヒツジにおけるP放出およびIVRのインビボ薬物動態および局所忍容性を評価すること、ならびに経膣投与されたCrinone8%ゲル(1.125gまたは90mgのP、Actavis Pharma、Parsippany,NJ)およびPrometrium200mgカプセル(Solvay Pharmaceuticals、Marietta,GA)を比較することであった。プラセボIVR群からのデータも比較として収集した。
Pの血漿中濃度(該当する場合)を測定するための血液サンプルをすべての動物から採取した。採血前に動物を絶食させなかった。1群~6群のサンプルは、卵巣摘出手術の前の-14日目に採取した(卵巣摘出の成功を確認するため)。1群および2群では、血漿は、投与前14日目、再度投与前7日目、および投与後1、2、4、8、12、24時間に採取した。3群では、血漿は、投与前1日目、投与後1、4、336、および672時間に採取した。4、5、および6群では、IVRの挿入前(0時間)、および投与後2、4、8、12、24、48、72、168、240、336時間(除去前)に血漿を採取した。
すべての動物の外陰部(外陰部および前庭の外部から見える部分)を、すべてのテスト品の投与前に検査し、毎日の検査を、毎日のリングチェックまたは製品投与前の2日目~29日目に行った。外部膣を、刺激の肉眼的徴候(すなわち、紅斑および浮腫)および局所的または全身的影響の他の徴候について観察した。刺激をDraizeスケールに基づいて採点し[14]、紅斑および浮腫の形成は、0(なし)~4(重度)のスケールで評価した。29日目の剖検でも同じスケールを使用して、内膣の刺激を記録し(生存中評価では見えない部分)、局所的または全身的影響の他の徴候も記録した。
29日目に、外部膣刺激スコアリングおよびリング除去に続いて、すべての群の動物を安楽死させた。剖検時に、生殖器官および周辺組織の肉眼検査を行い、子宮、子宮頸部、および膣を収集し、10%中性緩衝ホルマリンで固定した。生殖組織の顕微鏡検査は、委員会認定の獣医病理学者(JDV)によって、日常的に処理されたヘマトキシリンおよびエオシン染色されたスライドで行われた。
データの統計分析は、記述統計の計算に限定され、平均値、標準偏差(SD)、各群の群サイズおよび期間(連続エンドポイント)、ならびに各群および期間(カテゴリカルエンドポイント)の中央値またはインシデント数のいずれかを含んでいた。
1.Lawn JE,Gravett MG,Nunes TM,Rubens CE,Stanton C,Group tGR.Global report on preterm birth and stillbirth(1of7):definitions,description of the burden and opportunities to improve data.BMC Pregnancy and Childbirth.2010;10(1):S1.doi:10.1186/1471-2393-10-s1-s1.
2.Preterm birth.Centers for Disease Control and Prevention.2016..Accessed 13 August 2018 2018.
3.Infant Mortality.Centers for Disease Control and Prevention.2016.Accessed 13 August 2018 2018.
4.March of Dimes.Save the Childre.Born Too Soon:The Global Action Report on Preterm Birth.In:Howson C,Kinney M,Lawn J,editors.Geneva:WHO;2012.
5.Blanks AM,Brosens JJ.Progesterone action in the myometrium and decidua in preterm birth.Facts Views Vis Obgyn.2012;4(3):33-43.
6.Gellersen B,Fernandes MS,Brosens JJ.Non-genomic progesterone actions in female reproduction.Human Reproduction Update.2009;15(1):119-38.doi:10.1093/humupd/dmn044.
7.Caritis SN,Feghali MN,Grobman WA,Rouse DJ.What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.Seminars in Perinatology.2016;40(5):273-80..
8.Fonseca EB,Celik E,Parra M,Singh M,Nicolaides KH.Progesterone and the Risk of Preterm Birth among Women with a Short Cervix.New England Journal of Medicine.2007;357(5):462-9.doi:10.1056/NEJMoa067815.
9.De Franco EA,O’Brien JM,Adair CD,Lewis DF,Hall DR,Fusey S et al.Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix:a secondary analysis from a randomized,double-blind,placebo-controlled trial.Ultrasound in Obstetrics&Gynecology.2007;30(5):697-705.doi:doi:10.1002/uog.5159.
10.Hassan SS,Romero R,Vidyadhari D,al.e.Vaginal progesterone reduces the rate of preterm birth with sonographic short cervix:a multicenter,randomized,double-blind,placebo-controlled trial.Ultrasound in Obstetrics&Gynecology.2011;38(1):18-31.doi:doi:10.1002/uog.9017.
11.Winer N,Bretelle F,Senat M-V,Bohec C,Deruelle P,Perrotin F et al.17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix:a randomized controlled trial.American Journal of Obstetrics&Gynecology.2015;212(4):485.e1-.e10.doi:10.1016/j.ajog.2014.10.1097.
12.Grobman WA,Thom EA,Spong CY,Iams JD,Saade GR,Mercer BM et al.17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30mm.American Journal of Obstetrics&Gynecology.2012;207(5):390.e1-.e8.doi:10.1016/j.ajog.2012.09.013.
13.Kimball AB,Javorsky E,Ron ES,Crowley W,Langer R.A novel approach to administration of peptides in women:Systemic absorption of a GnRH agonist via transvaginal ring delivery system.Journal of Controlled Release.2016;233:19-28..
14.Draize JH,Woodard G,Calvery HO.Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes.Journal of Pharmacology and Experimental Therapeutics.1944;82(3):377-90.
15.Eckstein P,Jackson MCN,Millman N,Sobrero AJ.Comparison of vaginal tolerance tests of spericidal preparations in rabbits and monkeys.Journal of Reproduction and Fertility.1969;20(1):85-93.doi:10.1530/jrf.0.0200085.
16.Blencowe H,Cousens S,Chou D,Oestergaard M,Say L,Moller A-B et al.Born Too Soon:The global epidemiology of 15million preterm births.Reproductive Health.2013;10(1):S2.doi:10.1186/1742-4755-10-s1-s2.
17.Sipola-Leppanen M,Vaarasmaki M,Tikanmaki M,Matinolli H-M,Miettola S,Hovi P et al.Cardiometabolic Risk Factors in Young Adults Who Were Born Preterm.American Journal of Epidemiology.2015;181(11):861-73.doi:10.1093/aje/kwu443.
18.Tikanmaki M,Tammelin T,Sipola-Leppanen M,Kaseva N,Matinolli H-M,Miettola S et al.Physical Fitness in Young Adults Born Preterm.Pediatrics.2016;137(1).doi:10.1542/peds.2015-1289.
19.Norman M.Preterm birth and the shape of the heart.Circulation.2013;127(2):160-1.doi:10.1161/CIRCULATIONAHA.112.152827.
20.Romero R,Nicolaides K,Conde-Agudelo A,Tabor A,O’Brien JM,Cetingoz E et al.Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity:a systematic review and metaanalysis of individual patient data.American Journal of Obstetrics&Gynecology.2012;206(2):124.e1-.e19.doi:10.1016/j.ajog.2011.12.003.
21.Conde-Agudelo A,Romero R,Nicolaides K,Chaiworapongsa T,O’Brien JM,Cetingoz E et al.Vaginal progesterone vs cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix,previous preterm birth,and singleton gestation:a systematic review and indirect comparison metaanalysis.American Journal of Obstetrics&Gynecology.2013;208(1):42.e1-.e18.doi:10.1016/j.ajog.2012.10.877.
22.Dodd JM,Jones L,Flenady V,Cincotta R,Crowther CA.Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth.Cochrane Database of Systematic Reviews.2013(7).doi:10.1002/14651858.CD004947.pub3.
23.Nguyen BT,Jensen JT.Evaluating the efficacy and safety of a progestin-and estrogen-releasing ethylene vinyl acetate copolymer contraceptive vaginal ring.Expert Opinion on Drug Safety.2014;13(10):1423-30.doi:10.1517/14740338.2014.948842.
24.Roumen FJME,Mishell DR.The contraceptive vaginal ring,NuvaRing(登録商標),a decade after its introduction.The European Journal of Contraception&Reproductive Health Care.2012;17(6):415-27.doi:10.3109/13625187.2012.713535.
25.Brache V,Faundes A.Contraceptive vaginal rings:a review.Contraception.2010;82(5):418-27.doi:10.1016/j.contraception.2010.04.012.
26.van Laarhoven JAH,Kruft MAB,Vromans H.In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring.International Journal of Pharmaceutics.2002;232(1):163-73..
27.Matlin SA,Belenguer A,Hall PE.Progesterone-releasing vaginal rings for use in postpartum contraception.I.In vitro release rates of progesterone from core-loaded rings.Contraception.1992;45(4):329-41.doi:10.1016/0010-7824(92)90055-X.
28.Nath A,Sitruk-Ware R.Progesterone vaginal ring for contraceptive use during lactation.Contraception.2010;82(5):428-34.doi:10.1016/j.contraception.2010.05.016.
29.RamaRao S,Clark H,Merkatz R,Sussman H,Sitruk-Ware R.Progesterone vaginal ring:introducing a contraceptive to meet the needs of breastfeeding women.Contraception.2013;88(5):591-8.doi:10.1016/j.contraception.2013.05.004.
30.Carr SL,Gaffield ME,Dragoman MV,Phillips S.Safety of the progesterone-releasing vaginal ring(PVR)among lactating women:A systematic review.Contraception.2016;94(3):253-61.doi:10.1016/j.contraception.2015.04.001.
31.Dragonis C,Maltaris T,Binder H,Kat M,Mueller A,Cupisti S et al.Progesterone bioavailability with a progesterone-releasing silicone vaginal ring in IVF candidates.European Journal of Medical Research.2007;12:264-7.
32.Stadtmauer L,Silverberg KM,Ginsburg ES,Weiss H,Howard B.Progesterone vaginal ring versus vaginal gel for luteal support with invitro fertilization:a randomized comparative study.Fertility and Sterility.2013;99(6):1543-9.doi:10.1016/j.fertnstert.2012.12.052.
33.Stadtmauer L,Harrison DD,Boyd J,Bocca S,Oehninger S.Pilot study evaluating a progesterone vaginal ring for luteal-phase replacement in donor oocyte recipients.Fertility and Sterility.2009;92(5):1600-5.doi:10.1016/j.fertnstert.2008.08.085.
34.Stadtmauer L,Waud K.Progesterone Vaginal Ring for Luteal Support.Journal of Obstetrics and Gynaecology of India.2015;65(1):5-10.doi:10.1007/s13224-014-0634-0.
35.Zegers-Hochschild F,Balmaceda JP,Fabres C,Alam V,Mackenna A,Fernandez E et al.Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation.Human Reproduction.2000;15(10):2093-7.doi:10.1093/humrep/15.10.2093.
36.Romero R,Nicolaides KH,Conde-Agudelo A,O’Brien JM,Cetingoz E,Da Fonseca E et al.Vaginal progesterone decreases preterm birth≦34weeks of gestation in women with a singleton pregnancy and a short cervix:an updated meta-analysis including data from the OPPTIMUM study.Ultrasound in Obstetrics&Gynecology.2016;48(3):308-17.doi:doi:10.1002/uog.15953.
37.Norman JE,Bennett P.Preterm birth prevention-Time to PROGRESS beyond progesterone.PLOS Medicine.2017;14(9):e1002391.doi:10.1371/journal.pmed.1002391.
Claims (32)
- エチレン酢酸ビニル(EVA)、腟内リング(IVR)であって、前記リングが少なくとも2つのセグメント/ファイバーを含み、1つのセグメントがプロゲステロン(P)またはP等価物を含む、EVA膣内リング。
- 前記EVAリングが挿入の1日後に約4mg/日~約12mg/日のPを放出することをさらに含む、請求項1に記載のEVAリング。
- 前記EVAリングが挿入の1日後に約4mg/日のPを放出する、請求項2に記載のEVAリング。
- 前記EVAリングが挿入の1日後に約8mg/日のPを放出する、請求項1に記載のEVAリング。
- 前記EVAリングが挿入の1日後に約12mg/日のPを放出する、請求項1に記載のEVAリング。
- Pを含む前記EVAセグメントが約27%w/wの最終薬物負荷でEVA(約28%酢酸ビニル含有量)を使用して調製される、請求項1~5のいずれか一項に記載のEVAリング。
- Pを含む前記EVAセグメントは、長さが約74.5mm~約156.0mmである、請求項1~6のいずれか一項に記載のEVAリング。
- Pを含む前記EVAセグメントは、長さが約74.5mm~約148.5mmである、請求項7に記載のEVAリング。
- Pを含む前記EVAセグメントが約74.5mm、約148.5mmおよび約156.0mmからなる群から選択される、請求項7に記載のEVAリング。
- 前記リングは、直径が約57mmであり、断面直径が約5mmである、請求項1~9のいずれか一項に記載のEVAリング。
- Pの放出の速度が約2日~約14日の期間にわたり、約4mg/日、約8mg/日、または約12mg/日からのものである、請求項2に記載のEVAリング。
- 4mg/日のプロゲステロンセグメント化IVRの放出速度が0~24時間では約20.5±2.2、2~14日目では約3.8±1.3、かつ14日目には約2.3±1.5である、請求項11に記載のEVAリング。
- 8mg/日のプロゲステロンセグメント化IVRの放出速度が0~24時間では約38.4±3.3、2~14日目では約7.4±2.4、かつ14日目には約4.7±1.9である、請求項11に記載のEVAリング。
- 12mg/日のプロゲステロンセグメント化IVRの放出速度が0~24時間では約60.5±2.5、2~14日目では約11.5±2.8、かつ14日目には約7.3±3.8である、請求項11に記載のEVAリング。
- 4mg/日のプロゲステロンセグメント化IVRのCmax(pg/ml)が約969±145であることをさらに含む、請求項3に記載のEVAリング。
- AUC0~336時間のpg時間/mlが約153,000±38,900であることをさらに含む、請求項15に記載のEVAリング。
- CAVG(pg/ml)が約455±116であることをさらに含む、請求項16に記載のEVAリング。
- Tmax(時間)が約12であることをさらに含む、請求項17に記載のEVAリング。
- 8mg/日のプロゲステロンセグメント化IVRのCmax(pg/ml)が約1,820±469であることをさらに含む、請求項4に記載のEVAリング。
- AUC0~336時間が229,000±40,700であることをさらに含む、請求項19に記載のEVAリング。
- CAVGが約682±121であることをさらに含む、請求項20に記載のEVAリング。
- Tmaxが約2であることをさらに含む、請求項21に記載のEVAリング。
- 12mg/日のプロゲステロンセグメント化IVRのCmax(pg/ml)が約2,520±432であることをさらに含む、請求項5に記載のEVAリング。
- AUC0~336時間(pg時間/ml)が約350,000±73,900であることをさらに含む、請求項23に記載のEVAリング。
- CAVG(pg/ml)が約1,040±220であることをさらに含む、請求項24に記載のEVAリング。
- Tmax(時間)が約4であることをさらに含む、請求項25に記載のEVAリング。
- 前記リングは、治療されている対象が子宮頸管長短縮を有する、早産を予防するために使用される、請求項1~26のいずれか一項に記載のEVAリング。
- 前記リングが黄体機能不全を治療もしくは改善するために、または黄体期補助として使用される、請求項1~26のいずれか一項に記載のEVAリング。
- 前記黄体期補助が生殖補助医療とともに使用される、請求項28に記載のEVAリング。
- 前記黄体機能不全が卵胞刺激ホルモン(FSH)レベルの低下、FSH/黄体形成ホルモン(LH)比の変化、または異常なFSHおよびLHの拍動性と関連している、請求項29に記載のEVAリング。
- 前記異常なFSHおよびLHの拍動性が、視床下部性無月経、甲状腺およびプロラクチンの障害、肥満および多嚢胞性卵巣症候群(PCOS)、ならびにIVFサイクルの調節卵巣刺激法(COS)によって引き起こされる、請求項30に記載のEVAリング。
- 閉経に達していないが、体内のプロゲステロンの不足のために月経(period)を有しない女性において月経期(menstrual period)を引き起こすために、またはエストロゲン補充療法を受けている閉経後の女性において子宮内膜の異常増殖を予防するために、前記リングが使用される、請求項1~25のいずれか一項のEVAリング。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962826978P | 2019-03-29 | 2019-03-29 | |
US62/826,978 | 2019-03-29 | ||
US201962843288P | 2019-05-03 | 2019-05-03 | |
US62/843,288 | 2019-05-03 | ||
PCT/US2020/025837 WO2020205803A1 (en) | 2019-03-29 | 2020-03-30 | Eva segmented intravaginal rings containing progesterone |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022525439A true JP2022525439A (ja) | 2022-05-13 |
Family
ID=72666444
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021560625A Pending JP2022525439A (ja) | 2019-03-29 | 2020-03-30 | プロゲステロンを含むevaセグメント化膣内リング |
JP2021560627A Pending JP2022527411A (ja) | 2019-03-29 | 2020-03-30 | セグメント化されたeva膣内リング |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021560627A Pending JP2022527411A (ja) | 2019-03-29 | 2020-03-30 | セグメント化されたeva膣内リング |
Country Status (9)
Country | Link |
---|---|
US (3) | US20210000641A1 (ja) |
EP (2) | EP3946594A4 (ja) |
JP (2) | JP2022525439A (ja) |
CN (2) | CN114126551A (ja) |
AU (2) | AU2020252104A1 (ja) |
BR (2) | BR112021019493A2 (ja) |
CA (2) | CA3135362A1 (ja) |
MX (2) | MX2021011885A (ja) |
WO (2) | WO2020205803A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220133177A (ko) * | 2019-11-18 | 2022-10-04 | 데어 바이오사이언스, 인크. | 질내 링 장치 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4898431B2 (ja) * | 2003-04-29 | 2012-03-14 | ザ ジェネラル ホスピタル コーポレイション | 複数薬物の持続放出のための方法およびデバイス |
CA2771944A1 (en) * | 2003-07-16 | 2005-01-27 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
US8268806B2 (en) * | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
AU2012204083C1 (en) * | 2007-08-10 | 2015-02-05 | Myriel Pharmaceuticals, Llc | DHEA compositions for treating menopause |
-
2020
- 2020-03-30 JP JP2021560625A patent/JP2022525439A/ja active Pending
- 2020-03-30 MX MX2021011885A patent/MX2021011885A/es unknown
- 2020-03-30 CN CN202080032271.9A patent/CN114126551A/zh active Pending
- 2020-03-30 US US16/835,282 patent/US20210000641A1/en not_active Abandoned
- 2020-03-30 MX MX2021011884A patent/MX2021011884A/es unknown
- 2020-03-30 WO PCT/US2020/025837 patent/WO2020205803A1/en unknown
- 2020-03-30 EP EP20782894.8A patent/EP3946594A4/en active Pending
- 2020-03-30 EP EP20781826.1A patent/EP3952802A4/en active Pending
- 2020-03-30 AU AU2020252104A patent/AU2020252104A1/en active Pending
- 2020-03-30 BR BR112021019493A patent/BR112021019493A2/pt unknown
- 2020-03-30 AU AU2020256291A patent/AU2020256291A1/en active Pending
- 2020-03-30 WO PCT/US2020/025839 patent/WO2020205805A1/en unknown
- 2020-03-30 CA CA3135362A patent/CA3135362A1/en active Pending
- 2020-03-30 CN CN202080032294.XA patent/CN114126710A/zh active Pending
- 2020-03-30 BR BR112021019560A patent/BR112021019560A2/pt unknown
- 2020-03-30 CA CA3135163A patent/CA3135163A1/en active Pending
- 2020-03-30 JP JP2021560627A patent/JP2022527411A/ja active Pending
- 2020-03-30 US US16/835,251 patent/US20210007976A1/en not_active Abandoned
-
2023
- 2023-12-08 US US18/533,280 patent/US20240115416A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3952802A1 (en) | 2022-02-16 |
MX2021011884A (es) | 2022-01-24 |
CA3135362A1 (en) | 2020-10-08 |
CA3135163A1 (en) | 2020-10-08 |
EP3952802A4 (en) | 2023-01-04 |
AU2020256291A1 (en) | 2021-11-18 |
JP2022527411A (ja) | 2022-06-01 |
US20240115416A1 (en) | 2024-04-11 |
WO2020205805A1 (en) | 2020-10-08 |
WO2020205803A1 (en) | 2020-10-08 |
CN114126710A (zh) | 2022-03-01 |
MX2021011885A (es) | 2022-04-18 |
BR112021019560A2 (pt) | 2021-12-21 |
BR112021019493A2 (pt) | 2021-12-07 |
EP3946594A1 (en) | 2022-02-09 |
CN114126551A (zh) | 2022-03-01 |
US20210007976A1 (en) | 2021-01-14 |
AU2020252104A1 (en) | 2021-11-18 |
US20210000641A1 (en) | 2021-01-07 |
EP3946594A4 (en) | 2023-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Drillich et al. | Treatment of chronic endometritis in dairy cows with an intrauterine application of enzymes: A field trial | |
Benzaquen et al. | Rectal temperature, calving-related factors, and the incidence of puerperal metritis in postpartum dairy cows | |
Refsdal | To treat or not to treat: a proper use of hormones and antibiotics | |
Gumen et al. | Effect of presynchronization strategy before Ovsynch on fertility at first service in lactating dairy cows | |
Stojanović et al. | Normal vaginal flora, disorders and application of probiotics in pregnancy | |
Thomson et al. | Randomised trial of nitric oxide donor versus prostaglandin for cervical ripening before first-trimester termination of pregnancy | |
Tsai et al. | Progesterone elevation on the day of human chorionic gonadotropin administration is not the only factor determining outcomes of in vitro fertilization | |
Bugalho et al. | Termination of pregnancies of< 6 weeks gestation with a single dose of 800 μg of vaginal misoprostol | |
El-Tarabany et al. | Impact of thermal stress on the efficiency of ovulation synchronization protocols in Holstein cows | |
Hashem et al. | Oestrous response and characterization of the ovulatory wave following oestrous synchronization using PGF2α alone or combined with GnRH in ewes | |
Hashem et al. | Effects of a single administration of different gonadotropins on day 7 post-insemination on pregnancy outcomes of rabbit does | |
Pereira et al. | Effect of methotrexate or salpingectomy for ectopic pregnancy on subsequent in vitro fertilization–embryo transfer outcomes | |
KR20170021929A (ko) | 조산 예방에 유용한 지속적, 서방성, 및 연속 방출의 프로게스테론 함유 원형 결찰 페서리 | |
JP2022525439A (ja) | プロゲステロンを含むevaセグメント化膣内リング | |
Pymar et al. | Alternatives to mifepristone regimens for medical abortion | |
Kuon et al. | Actions of progestins for the inhibition of cervical ripening and uterine contractions to prevent preterm birth | |
Breukelman et al. | Ultrasonographic appearance of the conceptus, fetal heart rate and profiles of pregnancy-associated glycoproteins (PAG) and prostaglandin F2α-metabolite (PGF2α-metabolite) after induction of fetal death with aglepristone during early gestation in cattle | |
Palomares et al. | Oxytocin treatment immediately after calving does not reduce the incidence of retained fetal membranes or improve reproductive performance in crossbred Zebu cows | |
Weiss et al. | Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep | |
Abd‐El‐Maeboud et al. | Effect of vaginal pH on the efficacy of vaginal misoprostol for induction of midtrimester abortion | |
Bas et al. | Effect of intrauterine administration of gonadotropin releasing hormone on serum LH concentrations in lactating dairy cows | |
Chantraine et al. | Expulsion of a uterine myoma in a patient treated with ulipristal acetate | |
Garfield et al. | Diagnosis and effective management of preterm labor | |
Pandey et al. | Impact of buserelin acetate or hCG administration on day 5 post-ovulation on subsequent luteal profile and conception rate in Murrah buffalo (Bubalus bubalis) | |
Carlo et al. | Progestogens in preterm labour prevention: an update |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211007 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230202 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240126 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240426 |